Iconovo AB

Equities

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 08/07/2024 BST			5-day change	1st Jan Change
8.68 ^SEK	+0.23%		-6.06%	-24.85%

05-15	Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	CI
05-06	Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	MT

ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH

May 24, 2024 at 04:35 pm

The abbreviated annual report 2023 in English is attached to this press release and is now available on the company's website, www.iconovo.se.

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).

Latest news about Iconovo AB

Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	05-15	CI
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	05-06	MT
Iconovo AB Receives Patent Protection for Icores in China	05-06	CI
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	03-11	CI
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	02-07	CI
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	02-06	CI
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	02-01	CI
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD	11-16	CI
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23	CI
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone	26/09/23	CI
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations	19/09/23	CI
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre	13/09/23	CI
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027	23/08/23	CI
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership	17/08/23	MT
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease	17/08/23	CI
Iconovo AB, Provides Earnings Guidance for 2024 and 2025	16/08/23	CI
Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/07/23	CI
Iconovo Increases Sales Efforts and Supply Chain Security for ICOcap Through Restructured Agreement with Stevanato	13/07/23	CI
Iconovo Initiates Collaboration with Affilogic	22/06/23	CI
Sweden's Iconovo to Conduct Feasibility Study on New Treatment of Rare Disease	09/06/23	MT
Iconovo AB Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment	01/06/23	CI
Iconovo AB Announces Appoints Carl Lindgren as Chief Business Development Officer	23/05/23	CI

Chart Iconovo AB

Duration

Period

More charts

Company Profile

Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâs device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Sector

Medical Equipment, Supplies & Distribution

Calendar

11/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Iconovo AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Supplies

	1st Jan change	Capi.
ICONOVO AB	-24.85%	13.15M
COLOPLAST A/S	+11.40%	27.7B
HARTALEGA HOLDINGS	+25.93%	2.46B
INTCO MEDICAL TECHNOLOGY CO., LTD.	+16.57%	2.46B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-49.93%	2.24B
WINNER MEDICAL CO., LTD.	-33.88%	2.06B
TOP GLOVE CORPORATION BHD.	+32.22%	2.02B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-24.65%	1.65B
NAKANISHI INC.	+8.60%	1.36B
KOSSAN RUBBER INDUSTRIES	+32.97%	1.33B

Medical Supplies